Synlait Sold an Island to Save Itself — Now It Has to Sell Bulk Powder
FY26's ugly headline loss masks a genuine second-half operational turnaround; the open question is whether one Middle East infant-formula contract can replace what a2 Milk is taking away, and management won't price it.
SML.NZ · Earnings Call · 2026-09-27
Synlait's FY26 report is a story of a company that spent the year dismantling itself to survive and ended it claiming the worst is behind it. Chair George Adams was unusually direct at the top: “financially, this has been another difficult year for Synlait, and I appreciate that for our shareholders that is challenging news to hear.” — George Adams, Chair · 2026-09-27 The headline numbers justify the apology — a full-year net loss after tax of $75.4m, an underlying net loss of $21.6m, and negative operating cash flow of $183.3m.
A tale of two very different halves
The second half tells the opposite story. Reported EBITDA improved by $77.5m half-over-half; underlying EBITDA by $38.1m; reported net profit after tax swung by $85.8m. Manufactured-in-spec rose from 88% to 93%, production plan attainment from roughly 92% to 95.5%, and hit 99% in August. Acting CEO Leon Fung framed the year simply: “FY '26 was a difficult year financially. It was also a year of real progress in our recovery.” — Leon Fung, Acting CEO · 2026-09-27
That phrase — operational recovery — is the load-bearing claim of the whole call. If it is real, the first-half damage is a sunk cost and the second-half run-rate is the runway. If it is not, the company is simply a smaller, more indebted version of its former self. CFO Lei Liu's bridge was refreshingly honest about what actually went wrong: volume was never the issue; price and mix cost $7.3m and cost inflation ate $39.8m through lost fixed-cost recovery, quality spend and milk transport. Those are operating problems, and operating problems can be fixed. It is the structural ones that matter more.
An island sold, a baseline reset
The single cleanest positive is that the North Island sale is done — roughly $296m of cash proceeds, net debt down 14% to $215m, and a business now reduced to Dunsandel plus Dairyworks. The continuing operation is a $1.68bn revenue base doing $46.3m of underlying EBITDA, which management rightly calls the relevant baseline. Adams was blunt about the history: “it was also fairly that Pokeno was a significant drag on the business, and that drag has been eliminated.” — George Adams, Chair · 2026-09-27
But subtracting assets does not generate cash by itself, and the cash statement is ugly: negative $183.3m from operations, driven by a working-capital build in receivables and inventory. Liu was unambiguous that this is now the house priority — “the focus in the biggest one is the cash generation” — Lei Liu, CFO · 2026-09-27 — which is why the newly surfaced cash generation theme (rank 27 this quarter after not being a headline in prior periods) reads less as aspiration than as a warning. A company with $215m of net debt and covenant tests attached to it does not get to be patient about cash.
The cliff, and the contract meant to cover it
The strategic pivot is a forced one. a2 Milk is internalizing English-label production at its own Pokeno plant, and English label was the third-highest keyword on Synlait's board this quarter — an exit, not an entry. The replacement is a new Middle East customer, which Leon described as a significant, long-term-oriented buyer. The numbers given were specific: the contract represents 18% of FY'27 capacity, and Liu clarified it is “18% backfill the lost volumes or capacity and in 3 years' time, we can fully backfill” — Lei Liu, CFO · 2026-09-27.
Here is where the narrative strains. Synlait sells itself as a high-value nutrition story — the Advanced Nutrition arm was built on infant formula, adult nutrition and lactoferrin. Yet the marquee new customer is bulk. Asked directly, Leon confirmed: “It is in the bulk and the base powder” — Leon Fung, Acting CEO · 2026-09-27. He insisted the margin is good but declined to quantify it as commercially sensitive. Meanwhile Advanced Nutrition revenue was flat while gross profit collapsed 78%, on operational disruption, product-plan changes and lower lactoferrin sales. Leon called that unrepresentative — “The high cost or lower margin in the last financial year is not representative” — Leon Fung, Acting CEO · 2026-09-27 — and he may be right. But the symmetry is uncomfortable: the flagship division just lost three-quarters of its gross profit, and the celebrated backfill is the least differentiated product the company makes.
What management stopped saying
The most telling absence on this call was guidance. Synlait is moving to a December year-end and will report a five-month transitional period, and it will not guide that period at all. Adams was candid about why the silence has lasted: “We actually haven't given guidance for some time, and I think that was on the basis of us genuinely struggling to get our hands around operations.” — George Adams, Chair · 2026-09-27 A CEO promising to revisit guidance in February is a company admitting the visibility still is not there — even as Fung insists the second-half run-rate is sustainable when pressed by Macquarie's Nick Mar.
The other silences are just as informative. Covenant compliance was asserted but the EBITDA minimum milestones were refused outright; the a2 volume loss was refused as commercially sensitive; the working-capital release size was refused (though Liu conceded it “should be improved”). And the $0.38/kg milk-solid premium — the most direct lever on future profitability — was defended rather than softened, with Fung wrapping it in farmer loyalty language. On milk supply, management says it has the right volume and expects 3-6% above budget this season; Fung claims “we have the right amount of milk for our plant” — Leon Fung, Acting CEO · 2026-09-27, while Adams reframed last year's 6% production decline as artificial, caused by an inability to process peak rather than a shortage of cows.
Globally, Synlait's infant formula theme is shared — Australian packaged-food peer CLV.AX flagged the same category and vertical integration this quarter. What Synlait conspicuously does not share is the tariff-refund windfall now sweeping packaged-food reporters such as CBRL, COST and MLKN; with negligible US exposure, it sits outside that entire global conversation.
Strip it back and this is a small-cap (roughly NZ$261m) in the third year of a turnaround, finally showing operating traction but not yet cash, pivoting away from a customer it cannot afford to lose while the replacement takes three years to mature. The North Island sale bought time and cut debt. The next twelve months will show whether A2 volume loss plus a bulk-powder backfill is a diversification story or a margin-dilution story. Management is asking shareholders to trust the first without showing the math on the second — and the transition period will be reported with no guidance at all.